Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 6, 2012, Pages 803-818

  Sundin, Anders ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

11C 5 hydroxytryptophan; 68Ga; 68Ga DOTATOC; Computed tomography; CT; Endoscopic ultrasound; EUS; FDOPA; Magnetic resonance imaging; MRI; NET; Neuroendocrine tumour; OctreoScan; PET; Positron emission tomography; Scintigraphy; SPECT; Ultrasound; US

Indexed keywords

PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR;

ARTICLE; CANCER DIAGNOSIS; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; ECHOGRAPHY; GAMMA CAMERA; HUMAN; LIVER METASTASIS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREATIC NEUROENDOCRINE TUMOR; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84876129233     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.12.004     Document Type: Review

References (73)

1. B.I. Gustafsson, M. Kidd, and I.M. Modlin Neuroendocrine tumors of the diffuse neuroendocrine system Curr Opin Oncol 20 2008 1 12
2. I.M. Modlin, M. Kidd, I. Latich, M.N. Zikusoka, and M.D. Shapiro Current status of gastrointestinal carcinoids Gastroenterology 128 2005 1717 1751
3. J.C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, and J.E. Mares One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States J Clin Oncol 26 2008 3063 3072
4. A. Sundin, U. Garske, and H. Orlefors Nuclear imaging of neuroendocrine tumours Best Pract Res Clin Endocrinol Metab 21 2007 69 85
5. A. Sundin, M.P. Vullierme, G. Kaltsas, and U. Plöckinger ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations Neuroendocrinology 90 2009 167 183
6. A. Rinke, H.H. Müller, C. Schade-Brittinger, K.J. Klose, P. Barth, M. Wied PROMID Study Group Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 2009 4656 4663
7. D.J. Kwekkeboom, W.W. de Herder, and E.P. Krenning Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors Endocrinol Metab Clin North Am 40 2011 173 185
8. B. Kumbasar, I.R. Kamel, A. Tekes, J. Eng, E.K. Fishman, and R.L. Wahl Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS Abdom Imaging 29 2004 696 702
9. E.K. Paulson, V.G. McDermott, M.T. Keogan, D.M. DeLong, M.G. Frederick, and R.C. Nelson Carcinoid metastases to the liver: role of triple-phase helical CT Radiology 206 1998 143 150
10. J.L. Fidler, J.G. Fletcher, C.C. Reading, J.C. Andrews, G.B. Thompson, and C.S. Grant Preoperative detection of pancreatic insulinomas on multiphasic helical CT AJR Am J Roentgenol 181 2003 775 780
11. C. Dromain, T. de Baere, J. Lumbroso, H. Caillet, A. Laplanche, and V. Boige Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging J Clin Oncol 23 2005 70 78
12. M.D. Seemann, G. Meisetschlaeger, J. Gaa, and E.J. Rummeny Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI Eur J Med Res 11 2006 58 65
13. D. Elias, J.H. Lefevre, P. Duvillard, D. Goéré, C. Dromain, and F. Dumont Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination: they are many more than you think... Ann Surg 251 2010 307 310
14. F.L. Giesel, C. Kratochwil, A. Mehndiratta, S. Wulfert, J.H. Moltz, and C.M. Zechmann Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI Eur J Radiol 81 2012 2820 2825
15. T.R. Bader, R.C. Semelka, V.C. Chiu, D.M. Armao, and J.T. Woosley MRI of carcinoid tumors: spectrum of appearances in the gastrointestinal tract and liver J Magn Reson Imaging 14 2001 261 269
16. C. Dromain, T. de Baere, E. Baudin, J. Galline, M. Ducreux, and V. Boige MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques AJR Am J Roentgenol 180 2003 121 128
17. C. Caramella, C. Dromain, T. De Baere, B. Boulet, M. Schlumberger, and M. Ducreux Endocrine pancreatic tumours: which are the most useful MRI sequences? Eur Radiol 20 2010 2618 2627
18. E. Lopez Hänninen, H. Amthauer, N. Hosten, J. Ricke, M. Böhmig, and J. Langrehr Prospective evaluation of pancreatic tumors: accuracy of MR imaging with MR cholangiopancreatography and MR angiography Radiology 224 2002 34 41
19. A.G. Rockall, K. Planche, N. Power, E. Nowosinska, J.P. Monson, and A.B. Grossman Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI Neuroendocrinology 89 2009 288 295
20. C. Hoeffel, L. Job, V. Ladam-Marcus, F. Vitry, G. Cadiot, and C. Marcus Detection of hepatic metastases from carcinoid tumor: prospective evaluation of contrast-enhanced ultrasonography Dig Dis Sci 54 2009 2040 2046
21. S. Massironi, D. Conte, V. Sciola, L. Pirola, S. Paggi, and M. Fraquelli Contrast-enhanced ultrasonography in evaluating hepatic metastases from neuroendocrine tumours Dig Liver Dis 42 2010 635 641
22. C. De Angelis, P. Carucci, A. Repici, and M. Rizzetto Endosonography in decision-making and management of gastrointestinal endocrine tumors Eur J Ultrasound 10 1999 139 150
23. T. Ishikawa, A. Itoh, H. Kawashima, E. Ohno, H. Matsubara, and Y. Itoh Usefulness of EUS combined with contrast-enhancement in the differential diagnosis of malignant versus benign and preoperative localization of pancreatic endocrine tumors Gastrointest Endosc 71 2010 951 959
24. M.A. Khashab, E. Yong, A.M. Lennon, E.J. Shin, S. Amateau, and R.H. Hruban EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors Gastrointest Endosc 73 2011 691 696
25. A. Versari, L. Camellini, G. Carlinfante, A. Frasoldati, F. Nicoli, and E. Grassi Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study Clin Nucl Med 35 2010 321 328
26. M. Atiq, M.S. Bhutani, M. Bektas, J.E. Lee, Y. Gong, and E.P. Tamm EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience Dig Dis Sci 57 2012 791 800
27. S.A. Pais, M. Al-Haddad, M. Mohamadnejad, J.K. Leblanc, S. Sherman, and L. McHenry EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience Gastrointest Endosc 71 2010 1185 1193
28. D.J. Kwekkeboom, E.P. Krenning, K. Scheidhauer, V. Lewington, R. Lebtahi, and A. Grossman ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide Neuroendocrinology 90 2009 184 189
29. W.W. de Herder, D.J. Kwekkeboom, R. Valkema, R.A. Feelders, M.O. van Aken, and S.W. Lamberts Neuroendocrine tumors and somatostatin: imaging techniques J Endocrinol Invest 28 Suppl. 11 2005 132 136
30. V. Ambrosini, D. Campana, P. Tomassetti, G. Grassetto, D. Rubello, and S. Fanti PET/CT with 68Gallium-DOTA-peptides in NET: an overview Eur J Radiol 80 2011 e116 e119
31. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET Eur J Nucl Med Mol Imaging 39 Suppl. 1 2012 S52 S60
32. T.D. Poeppel, I. Binse, S. Petersenn, H. Lahner, M. Schott, and G. Antoch 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors J Nucl Med 52 2011 1864 1870
33. C. Boy, T.A. Heusner, T.D. Poeppel, A. Redmann-Bischofs, N. Unger, and W. Jentzen 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax Eur J Nucl Med Mol Imaging 38 2011 1224 1236
34. 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours Eur J Nucl Med Mol Imaging 38 2011 1659 1668
35. M. Miederer, S. Seidl, A. Buck, K. Scheidhauer, H.J. Wester, and M. Schwaiger Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT Eur J Nucl Med Mol Imaging 36 2009 48 52
36. M. Gabriel, C. Decristoforo, D. Kendler, G. Dobrozemsky, D. Heute, and C. Uprimny 68 Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 2007 508 518
37. I. Buchmann, M. Henze, S. Engelbrecht, M. Eisenhut, A. Runz, and M. Schäfer Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (OctreoScan) SPECT in patients with neuroendocrine tumours Eur J Nucl Med Mol Imaging 34 2007 1617 1626
38. R. Srirajaskanthan, I. Kayani, A.M. Quigley, J. Soh, M.E. Caplin, and J. Bomanji The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy J Nucl Med 51 2010 875 882
39. A. Frilling, G.C. Sotiropoulos, A. Radtke, M. Malago, A. Bockisch, and H. Kuehl The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors Ann Surg 252 2010 850 856
40. M.S. Hofman, G. Kong, O.C. Neels, P. Eu, E. Hong, and R.J. Hicks High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours J Med Imaging Radiat Oncol 56 2012 40 47
41. V. Ambrosini, D. Campana, L. Bodei, C. Nanni, P. Castellucci, and V. Allegri 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors J Nucl Med 51 2010 669 673
42. R. Kumar, P. Sharma, P. Garg, S. Karunanithi, N. Naswa, and R. Sharma Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours Eur Radiol 21 2011 2408 2416
43. N. Naswa, P. Sharma, A. Kumar, A.H. Nazar, R. Kumar, and S. Chumber Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study AJR Am J Roentgenol 197 2011 1221 1228
44. 111In-DTPA-octreotide (OctreoScan) Mol Imaging Biol 13 2011 583 593
45. V. Ambrosini, P. Tomassetti, P. Castellucci, D. Campana, G. Montini, and D. Rubello Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours Eur J Nucl Med Mol Imaging 35 2008 1431 1438
46. A. Haug, C.J. Auernhammer, B. Wängler, R. Tiling, G. Schmidt, and B. Göke Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours Eur J Nucl Med Mol Imaging 36 2009 765 770
47. H. Orlefors, A. Sundin, H. Ahlström, P. Bjurling, M. Bergström, and A. Lilja Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors J Clin Oncol 16 1998 2534 2541
48. H. Orlefors, A. Sundin, U. Garske, C. Juhlin, K. Oberg, and B. Skogseid Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography J Clin Endocrinol Metab 90 2005 3392 3400
49. K.P. Koopmans, O.C. Neels, I.P. Kema, P.H. Elsinga, W.J. Sluiter, and K. Vanghillewe Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography J Clin Oncol 26 2008 1489 1495
50. S. Adams, R. Baum, T. Rink, P.M. Schumm-Dräger, K.H. Usadel, and G. Hör Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours Eur J Nucl Med 25 1998 79 83
51. I. Kayani, J.B. Bomanji, A. Groves, G. Conway, S. Gacinovic, and T. Win Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG Cancer 112 2008 2447 2455
52. I. Kayani, B.G. Conry, A.M. Groves, T. Win, J. Dickson, and M. Caplin A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors J Nucl Med 50 2009 1927 1932
53. T. Binderup, U. Knigge, A. Loft, J. Mortensen, A. Pfeifer, and B. Federspiel Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET J Nucl Med 51 2010 704 712
54. E. Garin, F. Le Jeune, A. Devillers, M. Cuggia, A.S. de Lajarte-Thirouard, and C. Bouriel Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors J Nucl Med 50 2009 858 864
55. T. Binderup, U. Knigge, A. Loft, B. Federspiel, and A. Kjaer 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors Clin Cancer Res 16 2010 978 985
56. T. Masui, R. Doi, T. Ito, K. Kami, K. Ogawa, and D. Harada Diagnostic value of (18)F-fluorodeoxyglucose positron emission tomography for pancreatic neuroendocrine tumors with reference to the World Health Organization classification Oncol Lett 1 2010 155 159
57. I. Kamaoui, V. De-Luca, S. Ficarelli, N. Mennesson, C. Lombard-Bohas, and F. Pilleul Value of CT enteroclysis in suspected small-bowel carcinoid tumors AJR Am J Roentgenol 194 2010 629 633
58. A.A. Bailey, H.S. Debinski, M.N. Appleyard, M.L. Remedios, J.E. Hooper, and A.J. Walsh Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience Am J Gastroenterol 101 2006 2237 2243
59. F.A. Hakim, J.A. Alexander, J.E. Huprich, M. Grover, and F.T. Enders CT-enterography may identify small bowel tumors not detected by capsule endoscopy: eight years experience at Mayo Clinic Rochester Dig Dis Sci 56 2011 2914 2919
60. L. Pantongrag-Brown, P.C. Buetow, N.J. Carr, J.E. Lichtenstein, and J.L. Buck Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation AJR Am J Roentgenol 164 1995 387 391
61. M.A. Anderson, S. Carpenter, N.W. Thompson, T.T. Nostrant, G.H. Elta, and J.M. Scheiman Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas Am J Gastroenterol 95 2000 2271 2277
62. S. Rickes, K. Monkemuller, and P. Malfertheiner Contrast-enhanced ultrasound in the diagnosis of pancreatic tumors JOP 7 2006 584 592
63. S. Herwick, F.H. Miller, and A.L. Keppke MRI of islet cell tumors of the pancreas AJR Am J Roentgenol 187 2006 W472 W480
64. G.A. Poultsides, L.C. Huang, Y. Chen, B.C. Visser, R.K. Pai, and R.B. Jeffrey Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis Ann Surg Oncol 19 2012 2295 2303
65. Y. Wang, Z.E. Chen, V. Yaghmai, P. Nikolaidis, R.J. McCarthy, and L. Merrick Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics J Magn Reson Imaging 33 2011 1071 1079
66. W.H. Sommer, C.J. Zech, F. Bamberg, C.J. Auernhammer, A. Helck, and P.M. Paprottka Fluid-fluid level in hepatic metastases: a characteristic sign of metastases of neuroendocrine origin Eur J Radiol 81 2012 2127 2132
67. McDermott S, O'Neill AC, Skehan SJ. Staging of gastroenteropancreatic neuroendocrine tumors: how we do it based on an evidence-based approach. Clin Imaging, in press.
68. B. Taouli, and D.M. Koh Diffusion-weighted MR imaging of the liver Radiology 254 2010 47 66
69. R. Brenner, T. Metens, M. Bali, P. Demetter, and C. Matos Pancreatic neuroendocrine tumor: added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection Eur J Radiol 81 2012 e746 e749
70. E. Liapi, J.F. Geschwind, J.A. Vossen, M. Buijs, C.S. Georgiades, and D.A. Bluemke Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization AJR Am J Roentgenol 190 2008 67 73
71. A. Sundin, and A. Rockall Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead Neuroendocrinology 96 2012 261 271
72. M. Gabriel, A. Oberauer, G. Dobrozemsky, C. Decristoforo, D. Putzer, and D. Kendler 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy J Nucl Med 50 2009 1427 1434
73. A.R. Haug, C.J. Auernhammer, B. Wängler, G.P. Schmidt, C. Uebleis, and B. Göke 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors J Nucl Med 51 2010 1349 1356